66. (new) A compound of the formula



or a pharmaceutically acceptable salt thereof, wherein

is a 4-8 membered monocyclic ring or 7-12 membered bicyclic ring; which ring is optionally saturated or unsaturated, which ring is optionally substituted with one or more substituent selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, nitro, alkoxy, hydroxyalkyl, thioalkyl, amino, alkylamino, arylamino, alkylsulfonamide, acyl, acylamino, alkylsulfone, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, carboxamide, cyano, and $-(CH_2)_m$ COR;

m is 0 to 2;

R is hydroxy, alkoxy, alkyl or amino;

A^1 is a pyridinyl of the formula



optionally substituted by one or more R^k selected from the group consisting of hydroxy, alkyl, alkoxy, alkoxyalkyl, thioalkyl, haloalkyl, cyano, amino, alkylamino, halogen, acylamino, sulfonamide and -COR;

R is hydroxy, alkoxy, alkyl or amino;

with respect to Z^1 and Z^2:

Z^1 is selected from the group consisting of CH_2, O, N, CO, S, SO, SO_2,



and NR_k;

R_k is selected from H or lower alkyl;

Z^2 is a 2 to 5 carbon linker optionally containing one or more heteroatom selected from the group consisting of O, S and N; or

C1 cont

Z^1 - Z^2 contains a moiety selected from the group consisting of carboxamide, sulfone, sulfonamide, alkenylene, alkynylene, and acyl;

wherein the carbon and nitrogen atoms of Z^1 - Z^2 are optionally substituted by alkyl, alkoxy, thioalkyl, alkylsulfone, aryl, alkoxyalkyl, hydroxy, alkylamino, heteroaryl, alkenyl, alkynyl, carboxyalkyl, halogen, haloalkyl or acylamino;

A1

wherein Z_2 - Z_1 is attached to at the para or meta position relative to the X_1 substituent;

n is 0 to 2;

R^c is selected from the group consisting of hydrogen; alkyl; halogen, hydroxy, nitro, alkoxy, amino, haloalkyl, aryl, heteroaryl, alkoxyalkyl, aminoalkyl, hydroxyalkyl, thioalkyl, alkylamino, arylamino, alkylsulfonylamino, acyl, acylamino, sulfonyl, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, alkynylalkyl, carboxy, alkoxycarbonyl, carboxamido, cyano, and -$(CH_2)_m$ COR;

X^1 is selected from the group consisting of -O-, CO, SO_2, NR^m and $(CHR^p)_q$;

R^m is H or alkyl;

R^p is H, alkyl; alkoxy or hydroxy;

q is 0 or 1;

with respect to X, X^2 and Y:

X^2 is selected from the group consisting of -CHR^e-, CO, SO_2, O, NR^f and S;

R^f is H or alkyl;

R^e is selected from the group consisting of H, alkyl, hydroxy and alkoxy;

X or Y are independently selected from the group consisting of $-CR^9-$ or -N- wherein R^9 is selected from the group consisting of H, alkyl, haloalkyl, fluoro, alkoxyalkyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkylsulfone, hydroxyalkyl, hydroxy, alkoxy, and carboxyalkyl; or

the group $X-X_2-Y$ contains a moiety selected from the group consisting of acyl, alkyl, amino, ether, thioether, sulfone and olefin;



forms a 3-8 membered monocyclic ring system; or an 8-11 membered bicyclic system; optionally saturated or unsaturated; the monocyclic ring system optionally containing 1-2 heteroatoms selected from N, O and S; the bicyclic ring system optionally containing or optionally containing the group such as SO_2 or CO; and optionally substituted with one or more substituent selected from the group consisting of alkyl, halogen, cyano, carboalkoxy, haloalkyl, alkoxyalkyl, alkylsulfone, aryl, heteroaryl, arakyl, heteroarakyl, or alkoxy;

R^b is X_3 - R^h wherein X_3 is selected from the group consisting of O, S and NR^i wherein R^h and R^i are independently selected from the group consisting of H, alkyl, acyl, aryl, aralkyl and alkoxyalkyl.

67. A compound according to claim 66

wherein

A^1 is selected from the group consisting of



;

Z^a is selected from the group consisting of H, alkyl, alkoxy, hydroxy, amine, alkylamine, dialkylamine, carboxyl, alkoxycarbonyl, hydroxyalkyl, halogen and haloalkyl; and

R^1 is selected from the group consisting of H, alkyl, alkoxyalkyl, acyl, haloalkyl, alkoxycarbonyl, pyridylamino, imidazolylamino, morpholinopyridine, tetrahydronaphthyridine, oxazolylamino, thiazolylamino, pyrimidinylamino, quinoline, isoquinoline,

tetrahydroquinoline, imidazopyridine, benzimidazole, pyridone, and quinolone.

68. A compound according to claim 66

wherein

A^1 is selected from the group consisting of



;

X^4 is selected from the group consisting of H, alkyl, branched alkyl, alkylamino, aloxyalkylamino, haloalkyl, thioalkyl, halogen, amino, alkoxy, aryloxy, alkoxyalkyl, hydroxy, cyano and acylamino;

X^5 is selected from the group consisting of H, alkyl, branched alkyl, alkylamino, aloxyalkylamino, haloalkyl, thioalkyl, halogen, amino, alkoxy, aryloxy, alkoxyalkyl, hydroxy, cyano and acylamino;

X^6 is selected from the group consisting of H, alkyl, halogen, alkoxy, hydroxy, and haloalkyl; and

R^{79} is selected from the group consisting of hydroxy, alkoxy, alkyl and amino.

69. A compound according to the claim 66

wherein

the moiety A^1-Z^2 is selected from the group consisting of



;

X^4 is selected from the group consisting of H, alkyl, branched alkyl, alkylamino, aloxyalkylamino, haloalkyl, thioalkyl, halogen, amino, alkoxy, aryloxy, alkoxyalkyl, hydroxy, cyano and acylamino;

R^{80} is selected from the group consisting of hydroxy, alkoxy, alkyl and amino;

R^{81} is selected from the group consisting of hydroxy, alkoxy, alkyl and amino; and

R^{82} is selected from the group consisting of hydroxy, alkoxy, alkyl and amino.

70. A compound according to claim 66

wherein

X_1 is $(CHR^p)_q$; wherein q = 0;

B is a 3-, 4-, or a 5-membered ring obtained by combining X-X_2-Y;

A is a phenyl ring substituted with R^c;

n = 1

71. A compound according to claim 70,



wherein the ring B is a 3-member cyclopropyl ring;

$Y = CR^9$;

wherein R^9 is selected from the group consisting of H, alkyl, haloalkyl, alkoxyalkyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkylsulfone, hydroxyalkyl, hydroxy, alkoxy, and carboxyalkyl;

A is a phenyl ring substituted with R^c;

$R^b = OH$

72. A compound according to claim 71 wherein R^9 is selected from the group consisting of



H, alkyl, CH_2OH, $CH_2B_1R^{90}$,



R^{91} and CH_2R^{92} ;

R^{83} is selected from the group consisting of H, alkyl, OMe, OH, and halogen;

X^7 is selected from the group consisting of CH2 and O;

R^{84} is selected from the group consisting of H, alkyl, OMe, OH, and halogen;

R^{85} is selected from the group consisting of H, alkyl, OMe, OH, and halogen;

X^8 is selected from the group consisting of NH, NMe, O, and S;

R^{86} is selected from the group consisting of H and Me;

R^{87} is selected from the group consisting of H and Me;

R^{88} is selected from the group consisting of H, alkyl, OMe, OH, and halogen;

R^{89} is selected from the group consisting of H and Me;

B^1 is selected from the group consisting of O, SO2, S and CO;

R^{90} is selected from the group consisting of alkyl and aryl;

R^{91} is selected from the group consisting of alkyl and aryl; and

R^{92} is selected from the group consisting of aryl and heteroayl.

73. A compound according to claim 71

wherein

A^1 is selected from the group consisting of


and

;

X^9 is selected from the group consisting of H, alkyl, and acyl;

R^{93} is selected from the group consisting of H, Me, OH and alkoxyalkyl;

R^{93} is selected from the group consisting of H, Me, OMe, and OH.

74. A compound according to claim 71

wherein

ring A is a phenyl ring; and

Z_1-Z_2 and X_1-X are connected para to each other.

75. A compound according to claim 74 wherein the phenyl ring is optionally substituted with one or more substituents selected from the group consisting of alkyl; halogen, hydroxy, alkoxy, haloalkyl, aryl, heteroaryl, alkoxyalkyl, sulfonamide, methylenedioxy, ethylenedioxy, alkynyl, and alkynylalkyl.

76. A compound according to claim 74 wherein Z_1 is selected from the group consisting of CH_2, O, NR_k, CO, S, SO, and SO_2.

77. A compound according to claim 74 wherein A^1 is selected from the group consisting of


and


78. A compound according to the claim 66,



wherein

X^1 is $(CHR^p)_q$, wherein q = o;

A is a phenyl ring substituted with R^c

B is a 3-member ring obtained by combining $X\text{-}X_2\text{-}Y$;

n = 1

R_m and R_n are selected from the group consisting of H, alkyl, halogen, alkoxy, haloalkyl, alkoxyalkyl, alkylsulfone, cyano, carboalkoxy, aryl, heteroaryl, aralkyl and heteroaralkyl; or

R_m and R_n may from a spirocyclic ring system.

79. A compound according to the claim 78 wherein A^1 is selected from the group consisting of  ;

R^{94} is selected from the group consisting of H, Me, OH, and alkoxyalkyl;

R^{94} is selected from the group consisting of H, Me, OMe, and OH;

X^9 is selected from the group consisting of H, alkyl, and acyl.

80. A compound according to claim 66 selected from the group consisting of:

2-[4-[3-(2-pyridinylamino)propoxy]phenyl]cyclopropaneacetic acid;

2-[4-[3-(2-pyridinylamino)propoxy]phenyl] cyclopentaneacetic acid;

3-[4-[3-(2-pyridinylamino)propoxy]phenyl] cyclopentaneacetic acid;

2,2-difluoro-3-[4-[3(2-pyridinylamino)propoxy]phenyl]cyclopropane-acetic acid

(2-{4-[2-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid;

2-[3-methyl-4-[3-(2-pyridinylamino)propoxy]phenyl]cyclopropane-acetic acid;

2-[2-methoxy-4-[3-(2-pyridinylamino)propoxy]phenyl]cyclopropane-acetic acid;

3-bromo-5-fluoro- β , β -dimethyl-4-[3-(2-pyridinylamino)propoxy]-benzene butanoic acid;

2-[2-methyl-4-[3-(2-pyridinylamino)propoxy]phenyl]cyclopropane-acetic acid;

3-fluoro- β , β -dimethyl-4-[3-(2-pyridinylamino)propoxy]benzene-butanoic acid;

3-chloro- β , β -dimethyl-4-[3-(2-pyridinylamino)propoxy]benzene-butanoic acid;

2-[3-fluoro-4-[3-(2-pyridinylamino)propoxy]phenyl]cyclopropaneacetic acid;

2-[2-fluoro-4-[3-(2-pyridinylamino)propoxy]phenyl]cyclopropaneacetic acid;

β -methyl- β -[[4-[3-(2-pyridinylamino)propoxy]phenyl]methyl]-3-pyridine propanoic acid;

3-methoxy- β,β -dimethyl-4-[3-(2-pyridinylamino)propoxy]benzene-butanoic acid;

2-[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]cyclopropane-acetic acid;

2-[4-[2-(3,4-dihydro-2*H*-pyrido[3,2-*b*]-1,4-oxazin-6-yl)ethoxy]phenyl]-cyclopropaneacetic acid;

3-[4-[3-(2-pyridinylamino)propoxy]phenyl]cyclobutaneacetic acid;

(2-{2-Methoxy-4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid;

(2-{2-Fluoro-4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid;

(2-{2-Acetoxy-4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid;

(1-Methyl-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid;

(1-Methoxymethyl-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid;

(1-Methanesulfonylmethyl-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid;

(1-Pyridin-3-yl-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid;

(1-Benzo[1,3]dioxole-5-yl-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid;

(1-(2,3-Dihydro-benzofuran-6-yl)-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid;

(1-Isoxazol-3-yl-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid;

(1-Isoxazol-5-yl-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid;

(1-Oxazol-5-yl-2-{4-[3-(pyridin-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid;

(2-{4-[3-(Pyridin-2-ylamino)-propoxy]-phenyl}-1-thiazol-5-yl-cyclopropyl)-acetic acid;

(1-Pyridin-3-yl-2-{4-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid;

(1-Methyl-2-{4-[2-(6-methylamino-pyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid;

(2-{4-[2-(6-Ethylamino-pyridin-2-yl)-ethoxy]-phenyl}-1-methyl-cyclopropyl)-acetic acid;

[2-(4-{2-[6-(2-Methoxy-ethylamino)-pyridin-2-yl]-ethoxy}-phenyl)-1-methyl-cyclopropyl]-acetic acid;

[2-(4-{2-[6-(3-Methoxy-propylamino)-pyridin-2-yl]-ethoxy}-phenyl)-1-methyl-cyclopropyl]-acetic acid;

{2-{4-[2-(6-Acetylamino-pyridin-2-yl)-ethoxy]-phenyl}-1-methyl-cyclopropyl)-acetic acid;
[1-Methyl-2-(4-{2-[6-(2,2,2-trifluoro-ethylamino)-pyridin-2-yl]-ethoxy}-phenyl)-cyclopropyl]-acetic acid;
(2-{4-[2-(6-Ethylamino-pyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid
[2-(4-{2-[6-(2-Methoxy-ethylamino)-pyridin-2-yl]-ethoxy}-phenyl)-cyclopropyl]-acetic acid;
[2-(4-{2-[6-(2,2,2-Trifluoro-ethylamino)-pyridin-2-yl]-ethoxy}-phenyl)-cyclopropyl]-acetic acid;
[2-(4-{2-[6-(3-Methoxy-propylamino)-pyridin-2-yl]-ethoxy}-phenyl)-cyclopropyl]-acetic acid; and
(2-{4-[2-(6-Acetylamino-pyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid.

81. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 66 and a pharmaceutically acceptable carrier.

82. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 70 and a pharmaceutically acceptable carrier.

83. A method for treating conditions mediated by the $\alpha_v\beta_3$ integrin in a mammal in need of such treatment comprising administering an effective $\alpha_v\beta_3$ inhibiting amount of a compound of Claim 66.

84. A method for treating conditions mediated by the $\alpha_v\beta_3$ integrin in a mammal in need of such treatment compirisng administering an effective $\alpha_v\beta_3$ inhibiting amount of a compound of Claim 70.

85. The method according to Claim 83 wherein the condition treated is tumor metastasis.

86. The method according to Claim 84 wherein the condition treated is tumor metastasis.

87. The method according to Claim 83 wherein the condition treated is solid tumor growth.

88. The method according to Claim 84 wherein the condition treated is solid tumor growth.

89. The method according to Claim 83 wherein the condition treated is angiogenesis.

90. The method according to Claim 84 wherein the condition treated is angiogenesis.

91. The method according to Claim 83 wherein the condition treated is osteoporosis.

92. The method according to Claim 84 wherein the condition treated is osteoporosis.

93. The method according to Claim 83 wherein the condition treated is humoral hypercalcemia of malignancy.

94. The method according to Claim 84 wherein the condition treated is humoral hypercalcemia of malignancy.

95. The method according to Claim 83 wherein the condition treated is smooth muscle cell migration.

96. The method according to Claim 84 wherein the condition treated is smooth muscle cell migration.

97. The method according to Claim 83 wherein restenosis is inhibited.

98. The method according to Claim 84 wherein restenosis is inhibited.

99. The method according to Claim 83 wherein atherosclerosis is inhibited.

100. The method according to Claim 84 wherein atherosclerosis is inhibited.

101. The method according to Claim 83 wherein macular degeneration is inhibited.

102. The method according to Claim 84 wherein macular degeneration is inhibited.

103. The method according to Claim 83 wherein retinopathy is inhibited.

104. The method according to Claim 84 wherein retinopathy is inhibited.

105. The method according to Claim 83 wherein arthritis is inhibit d.

106. The method according to Claim 84 wherein arthritis is inhibited.

107. A method for treating conditions mediated by the $\alpha_v\beta_5$ integrin in a mammal in need of such treatment comprising administering an effective $\alpha_v\beta_5$ inhibiting amount of a compound of Claim 66.

108. A method for treating conditions mediated by the $\alpha_v\beta_5$ integrin in a mammal in need of such treatment compirising administering an effective $\alpha_v\beta_5$ inhibiting amount of a compound of Claim 70.

109. The method according to Claim 107 wherein the condition treated is tumor metastasis.

110. The method according to Claim 108 wherein the condition treated is tumor metastasis.

111. The method according to Claim 107 wherein the condition treated is solid tumor growth.

112. The method according to Claim 108 wherein the condition treated is solid tumor growth.

113. The method according to Claim 107 wherein the condition treated is angiogenesis.

114. The method according to Claim 108 wherein the condition treated is angiogenesis.

115. The method according to Claim 107 wherein the condition treated is osteoporosis.

116. The method according to Claim 108 wherein the condition treated is osteoporosis.

C1 cont

117. The method according to Claim 107 wh rein the condition treated is humoral hypercalc mia of malignancy.

118. The method according to Claim 108 wherein the condition treated is humoral hypercalcemia of malignancy.

119. The method according to Claim 107 wherein the condition treated is smooth muscle cell migration.

A1

120. The method according to Claim 108 wherein the condition treated is smooth muscle cell migration.

121. The method according to Claim 107 wherein restenosis is inhibited.

122. The method according to Claim 108 wherein restenosis is inhibited.

123. The method according to Claim 107 wherein atherosclerosis is inhibited.

124. The method according to Claim 108 wherein atherosclerosis is inhibited.

125. The method according to Claim 107 wherein macular degeneration is inhibited.

126. The method according to Claim 108 wherein macular degeneration is inhibited.

127. The method according to Claim 107 wherein retinopathy is inhibited.

128. The method according to Claim 108 wherein retinopathy is inhibited.

128. The method according to Claim 107 wherein arthritis is inhibited.

130. The method according to Claim 108 wherein arthritis is inhibited.